Screening for Type 2 diabetes—should it be now?

Aims Screening for Type 2 diabetes has been recommended in several countries due to the increasing prevalence of diabetes. This review evaluates whether Type 2 diabetes is a disease that fulfils the criteria for screening set by the World Health Organization.

[1]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[2]  O. Pedersen,et al.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study , 1999, The Lancet.

[3]  R. Heller,et al.  Effectiveness and hazards of case finding for a high cholesterol concentration. , 1990, BMJ.

[4]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[5]  J. Bloom,et al.  Hypertension labeling and sense of well-being. , 1981, American journal of public health.

[6]  S. Keinänen-Kiukaanniemi,et al.  Random capillary whole blood glucose test as a screening test for diabetes mellitus in a middle-aged population. , 1995, Scandinavian journal of clinical and laboratory investigation.

[7]  D. Schriger,et al.  Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. , 1999, JAMA.

[8]  J. Tuomilehto,et al.  Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies , 1999 .

[9]  B. Howard,et al.  Effects of Diet and Exercise in Preventing NIDDM in People With Impaired Glucose Tolerance: The Da Qing IGT and Diabetes Study , 1997, Diabetes Care.

[10]  Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .

[11]  A. Mann,et al.  The Psychological Impact of Screening for Risk of Coronary Heart Disease in Primary Care Settings , 1998, Journal of Cardiovascular Risk.

[12]  L. Papoz,et al.  GHb (HbA(1c)) is more sensitive than fasting blood glucose as a screening test for diabetes. , 2000, Diabetes care.

[13]  R. Hayward,et al.  ESTIMATING THE MICROVASCULAR BENEFITS OF SCREENING FOR TYPE 2 DIABETES MELLITUS , 2000, International Journal of Technology Assessment in Health Care.

[14]  L. Bouter,et al.  Performance of an NIDDM Screening Questionnaire Based on Symptoms and Risk Factors , 1997, Diabetes Care.

[15]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[16]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[17]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[18]  M. Engelgau,et al.  A New and Simple Questionnaire to Identify People at Increased Risk for Undiagnosed Diabetes , 1995, Diabetes Care.

[19]  M. B. Brown,et al.  Use of GHb (HbA(1c)) to screen for undiagnosed diabetes in the U.S. population. , 2000, Diabetes care.

[20]  K. Flegal,et al.  Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. , 2000, Diabetes care.

[21]  S. Fowler,et al.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. , 2002 .

[22]  Nicholas J Wareham,et al.  Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria , 2001, BMJ : British Medical Journal.

[23]  M. Engelgau,et al.  Screening for type 2 diabetes. , 2000, Diabetes care.

[24]  N. Wareham,et al.  Diabetes risk score: towards earlier detection of Type 2 diabetes in general practice , 2000, Diabetes/metabolism research and reviews.

[25]  H. Lithell,et al.  Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data , 1998 .

[26]  B. Davis,et al.  Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.

[27]  E. Feskens,et al.  Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. , 2001, Archives of internal medicine.

[28]  E. Barrett-Connor,et al.  Evaluation of Fasting Plasma Glucose as Screening Test for NIDDM in Older Adults: Rancho Bernardo Study , 1991, Diabetes Care.

[29]  M. Engelgau,et al.  Screening for Diabetes Mellitus in Adults: The utility of random capillary blood glucose measurements , 1995, Diabetes Care.

[30]  H. Parving,et al.  Albuminuria and Poor Glycemic Control Predict Mortality in NIDDM , 1995, Diabetes.

[31]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[32]  R. Klein,et al.  Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis , 1992, Diabetes Care.

[33]  S. Keinänen-Kiukaanniemi,et al.  Prevalence of Retinopathy in People With Diabetes, Impaired Glucose Tolerance, and Normal Glucose Tolerance , 1998, Diabetes Care.

[34]  M. Engelgau,et al.  Diabetes trends in the U.S.: 1990-1998. , 2000, Diabetes care.

[35]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[36]  D. Sackett,et al.  Effects of labelling on income, work and social function among hypertensive employees. , 1984, Journal of chronic diseases.

[37]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[38]  R. Schrier,et al.  The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. , 1998, The New England journal of medicine.

[39]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.